牛牛AI助理已提取核心訊息
Adial Pharmaceuticals, Inc. (Adial), a Delaware-based pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on January 12, 2024. The registration statement, identified as Form S-3, includes a prospectus for the potential sale of various securities, which may comprise common stock, preferred stock, debt securities, warrants, and units. The company has not specified the total amount of securities to be offered or the timing of any sales, indicating that offerings will occur from time to time based on market conditions. The registration statement outlines the terms under which the securities may be offered, the use of proceeds, and the company's indemnification obligations to directors and officers. Adial has made provisions for the securities to be sold through underwriters, dealers, or directly to the public, with the possibility of book-entry or global securities issuance. The registration statement also includes financial statements audited by Marcum LLP and legal opinions by Blank Rome LLP.
Adial Pharmaceuticals, Inc. (Adial), a Delaware-based pharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on January 12, 2024. The registration statement, identified as Form S-3, includes a prospectus for the potential sale of various securities, which may comprise common stock, preferred stock, debt securities, warrants, and units. The company has not specified the total amount of securities to be offered or the timing of any sales, indicating that offerings will occur from time to time based on market conditions. The registration statement outlines the terms under which the securities may be offered, the use of proceeds, and the company's indemnification obligations to directors and officers. Adial has made provisions for the securities to be sold through underwriters, dealers, or directly to the public, with the possibility of book-entry or global securities issuance. The registration statement also includes financial statements audited by Marcum LLP and legal opinions by Blank Rome LLP.
總部位於特拉華州的製藥公司阿迪亞爾製藥公司（Adial）已於2024年1月12日向美國證券交易委員會（SEC）提交了註冊聲明。註冊聲明名爲S-3表格，包括可能出售各種證券的招股說明書，這些證券可能包括普通股、優先股、債務證券、認股權證和單位。該公司沒有具體說明要發行的證券總額或任何出售的時間，這表明將根據市場狀況不時進行發行。註冊聲明概述了證券發行的條款、所得款項的使用以及公司對董事和高級管理人員的賠償義務。Adial已規定證券可以通過承銷商、交易商或直接向公衆出售，並有可能進行賬面記賬或全球證券發行。註冊聲明還包括由Marcum LLP審計的財務報表和Blank Rome LLP的法律意見。
總部位於特拉華州的製藥公司阿迪亞爾製藥公司（Adial）已於2024年1月12日向美國證券交易委員會（SEC）提交了註冊聲明。註冊聲明名爲S-3表格，包括可能出售各種證券的招股說明書，這些證券可能包括普通股、優先股、債務證券、認股權證和單位。該公司沒有具體說明要發行的證券總額或任何出售的時間，這表明將根據市場狀況不時進行發行。註冊聲明概述了證券發行的條款、所得款項的使用以及公司對董事和高級管理人員的賠償義務。Adial已規定證券可以通過承銷商、交易商或直接向公衆出售，並有可能進行賬面記賬或全球證券發行。註冊聲明還包括由Marcum LLP審計的財務報表和Blank Rome LLP的法律意見。
有用
沒用